Free Trial
NASDAQ:NMRA

Neumora Therapeutics Q1 2024 Earnings Report

Neumora Therapeutics logo
$0.65 +0.02 (+2.67%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.63 -0.01 (-2.13%)
As of 04/17/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neumora Therapeutics EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.34
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Neumora Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neumora Therapeutics Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Neumora Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Monday, May 12, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Neumora Therapeutics Earnings Headlines

Can you still profit from AI this year? (Read this ASAP)
AI isn’t dead — it’s just getting started. Weiss Ratings — ranked #1 by both the SEC and the Wall Street Journal — just issued 3 new “Buy” signals on under-the-radar AI stocks. See the names and ticker symbols now (for free).
See More Neumora Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neumora Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your email.

About Neumora Therapeutics

Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

View Neumora Therapeutics Profile

More Earnings Resources from MarketBeat